GlassScriptPhysician profile
David Ralph Mandel
NPI 1558369553
$352,089.66
in general payments reported to CMS, 2019-2025
19 companies · $50K in 2025
The $50K reported for 2025 was more than what 96% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109K · 2020: $59K · 2021: $31K · 2022: $17K · 2023: $32K · 2024: $54K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $101K · Honoraria: $23K · Travel and Lodging: $8,678 · Food and Beverage: $3,628 · Consulting Fee: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100,859.00 |
| Honoraria | $22,550.00 |
| Travel and Lodging | $8,678.45 |
| Food and Beverage | $3,628.13 |
| Consulting Fee | $165.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $239,370.66 | 2019-2023 | Krystexxa |
| Amgen INC. | $77,336.31 | 2020-2025 | Krystexxa, Tavneos, Prolia |
| Genzyme Corporation | $33,200.68 | 2021-2025 | |
| Abbvie INC. | $614.70 | 2020-2024 | |
| Pfizer INC. | $278.73 | 2019-2023 | |
| Lilly USA, LLC | $261.19 | 2019-2024 | Taltz |
| Ucb, INC. | $218.82 | 2020-2023 | Cimzia |
| Genentech USA, INC. | $180.04 | 2020-2023 | Actemra |
| Janssen Biotech, INC. | $170.67 | 2022-2023 | Tremfya |
| Glaxosmithkline, LLC. | $165.00 | 2023 | Benlysta |
| Sobi, INC | $79.38 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $49.77 | 2020-2023 | Orencia |
| Radius Health, INC. | $38.65 | 2022-2023 | Tymlos |
| Mallinckrodt Enterprises LLC | $24.97 | 2019 | |
| Aurinia Pharma U.S., INC. | $22.58 | 2023 | Lupkynis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $20.07 | 2021 | |
| Hikma Pharmaceuticals USA | $20.07 | 2021 | |
| Ani Pharmaceuticals, INC. | $19.27 | 2022 | |
| Sandoz INC. | $18.10 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mandel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.